In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biovail, Kos sign series of CV and metabolic deals

Executive Summary

For $104mm, specialty pharma company Kos Pharmaceuticals has licensed US rights to three cardiovascular products and three candidates in the cardiovascular and metabolic areas from drug delivery company Biovail (focuses on CV and CNS disorders). The series of deals is part of Biovail's restructuring of its US primary care marketing operations.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register